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Rationale and objectives: COPD is associated with an increased risk of lung cancer. We exam-
ined whether inhaled corticosteroids (ICS) used concomitantly with long-acting beta2-agonists
(LABA) were associated with reduction in lung cancer risk in COPD patients.
Methods: We conducted a retrospective cohort study of patients with a first-time diagnosis of
COPD (index date) between 1989 and 2003 who were initially free of lung cancer, had quit
smoking, were aged 50 years at time of diagnosis, and were regular users of ICS, ICS/LABA
concomitantly, or short-acting bronchodilators (SABD). A nested caseecontrol design was
applied to overcome the time-varying nature of treatment.
Results: We identified 7079 COPD patients whowere regular users of the therapies of interest, of
whom 127 subsequently had lung cancer and were matched to 1470 controls of same gender and
age. Lung cancerwas diagnosed in 6.0% of concomitant ICS/LABAusers comparedwith 7.3% of ICS
and 10.9% of SABD users. In multivariate analyses, reductions in lung cancer risk were observed,
with hazard ratio (HR) 0.50 (95% confidence interval, 0.27e0.90) in ICS/LABA users and 0.64
(0.42e0.98) in ICS users, compared with SABD users. In assessing ‘doseeresponse’ relationships,
we found risk reductions: HRof 0.75 (0.33e1.75) and 0.39 (0.19e0.79) in ICS/LABAuserswith 1e2
and 3þ prescriptions/year, respectively, and 0.88 (0.51e1.52) and 0.51 (0.30e0.84) in ICS users
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Respiratory diseases accounted for one in five deaths
(approximately 117,500 in total) in the UK in 2004, resulting
in more deaths than coronary heart disease.1 Respiratory
mortality is primarily due to pneumonia (29%), lung cancer
(28%) and chronic obstructive pulmonary disease (COPD)
(20%). Whereas mortality due to coronary heart disease has
halved since 1984, death rates from respiratory disease
have remained constant during the same period.1 Respira-
tory diseases are associated with substantial morbidity and
economic burden in the UK (£6.6 billion in 2004). In 2004/
2005, COPD was responsible for over 108,000 emergency
hospital admissions, and this is projected to rise to almost
160,000 admissions by 2028, costing an estimated £376
million.2 COPD is currently the fourth leading cause of
worldwide mortality, responsible for more than 2.5 million
deaths per year and is expected to be the third leading
cause by 2020.3
The clinical epidemiology4e6 and pharmacoepidemiol-
ogy7 of COPD have been described using the UK General
Practice Research Database (GPRD) demonstrating the
significant burden of the disease and increasing prevalence
among women related to smoking patterns. Indeed, a more
recent study in another of the UK primary care databases
(the Health Improvement Network) indicates high preva-
lence of COPD, large increase in spirometry data and
significant progress in the overall management of the
disease.8
Lung cancer was responsible for 5.6% of all UK deaths in
2004, accounting for 24% of male and 18% of female cancer
deaths.1 Worldwide, 2.2% of deaths in 2004 were attributed
to lung cancer.2 Despite recent advances in the treatment
and diagnosis of lung cancer, prognosis is still very poor,
with 5-year overall survival generally less than 10% in many
countries, including the UK.9e11 A substantial body of
evidence suggests that COPD and impaired lung function
are associated with the occurrence of lung cancer12 e
notably, cigarette smoking is the principal cause of both
diseases. Accordingly, the single most important interven-
tion in management of COPD is smoking cessation, which
slows the rate of lung function decline and positively
impacts quality of life and survival.13
COPD is an inflammatory respiratory disease.14
A comprehensive review of studies on important pathoge-
netic mechanisms on the relationship between COPD and
lung cancer has been reported by Brody and Spira.15
Inflammation and lung cancer have also been linked, with
some studies suggesting that chronic inflammation plays
a role, at least partially, through mechanisms that are
independent of those associated with smoking-related
cancers.16,17 Another recent study has also suggested a role
for inflammation in the causal pathways for both COPD and
lung cancer.18 Therefore, it is possible that anti-
inflammatory therapies used to treat COPD may delay oreven prevent the onset of lung cancer in COPD patients.19
Only smoking cessation, and in some patients long-term
oxygen therapy and lung volume reduction surgery, has
been consistently shown to improve survival in COPD. Other
interventions such as pulmonary rehabilitation have not.20
Inhaled corticosteroids (ICS), alone or in combination with
a long-acting beta2-agonist (LABA), have a broad range of
anti-inflammatory effects in COPD patients, the combina-
tion more so than ICS alone.21,22 This combined effect leads
to a clinical benefit in many endpoints including symptoms,
lung function, exacerbations and quality of life,23 and
possibly increased survival, although the TORCH rando-
mised controlled trial did not indicate a reduction in
cancer.24
The objective of this study was to evaluate the associ-
ation between lung cancer incidence and the regular use of
ICS, alone and in concomitant use with an LABA, in COPD
patients who were former smokers.
Methods
Database setting and cohort definition
The GPRD is a large, automated database of general prac-
tices in the UK that continues to provide a unique source for
investigating the effects of therapy on disease from a ‘real
life’ perspective.6,25e29 We retrospectively identified all
patients with newly diagnosed COPD (index date) between
1989 and 2003, and free of lung cancer diagnosis up to the
index date. Only COPD patients who were reported by the
GP as former smokers, were aged 50 years or over at time of
COPD diagnosis and were regular users of either ICS, ICS/
LABA, or short-acting bronchodilators (SABD) were
selected. The inclusion and exclusion criteria are shown in
Table 1. Longitudinal records of identified patients were
obtained and followed up to incident lung cancer diagnosis,
death, left practice, or censoring as of 30 June 2005,
whichever was first.
Drug exposure and outcome
Drug exposure was defined in terms of prescription of ICS,
ICS/LABA or SABD and patients identified as regular users
were those with three or more prescriptions of the
respective drugs within 6 months of cohort entry. The
outcome of interest was incident diagnosis of lung cancer.
Study design
A nested caseecontrol design was used to overcome the
time-varying nature of treatment.30e32 Thus, the incident
diagnosed lung cancer cases were individually matched to
as many controls as were available from the COPD cohort of
the same age and gender in the corresponding risk sets.
Table 1 Inclusion and exclusion criteria.
Inclusion criteria
 Registered in the GPRD with one or more of the
validated OXMIS/READ codes defining COPD,
newly diagnosed between 1 January 1989 and
31 December 2003
 Age 50 years at COPD diagnosis
 Ex-smoker during the study observation period
 Initiation of regular ICS or ICS/LABA or SABD as
pharmacotherapy within 6 months of cohort entrya
Exclusion criterion
 Diagnosis of cystic fibrosis
a Cohort entry could be at diagnosis of COPD (if an ex-smoker
at first diagnosis) or at the time of smoking cessation.
Table 2 Descriptive characteristics of cases and their
controls.
Cases Controls
Total, n 127 1470
Female, % 36.2 35.5
Mean age at cohort entry,
years (SD)
70.7 (6.9) 70.8 (6.6)
Aged 50e59, % 4.7 4.1
Aged 60e69, % 41.7 41.2
Aged 70e79, % 44.1 45.3
Aged 80, % 9.4 9.3
Mean duration of COPD at
cohort entry, years (SD)
1.5 (1.6) 1.5 (2.1)
Mean duration of smoking
cessation, years (SD)
2.5 (3.7) 2.9 (4.0)
Baseline comorbidities, %
Asthma 51.2 57.8
Myocardial infarction 7.9 9.2
Congestive heart failure 13.4 13.8
Cerebrovascular disease 7.9 8.0
Dementia 0.8 0.4
Peptic ulcer 15.7 15.8
Peripheral vascular disease 5.5 5.2
Moderate/severe liver disease 0.0 0.3
Rheumatologic disease 36.2 36.5
Hemiplegia/paraplegia 0.0 0.9
Diabetes 5.5 8.0
Diabetes with complicationsa 1.6 0.8
Anxiety/depression 26.8 28.2
Renal disease 1.6 1.0
Users of COPD medications in
the first 6 months from
cohort entry, %b
ICS 63.8c 74.5
LABA 15.7 21.4
Antimuscarinics 30.7 35.5
SABD 80.3 81.2
Cromoglycate 0.8 0.5
Leukotriene modifiers 0.0 1.1
Theophyllines 7.9 8.6
Oral corticosteroids 38.6 39.3
Oxygen therapy 2.4 3.3
Nebulised therapy 3.1 2.3
Antibiotics 47.2 58.0
a Diabetes with end organ damage, including ketoacidosis and
coma.
b Percentage of persons with at least one prescription of the
drug in the period.
c P< 0.05 versus control group.
ICS and lung cancer risk in COPD 87Controls had to be at risk of developing lung cancer at the
time of lung cancer diagnosis of the case to which they
were matched; duration of treatment (i.e. period of
assessment of treatment) was also the same for both case
and matched controls. Each control was required to have at
least a long history of COPD as its matched case. Analysis
was confined to primary lung cancer as per the Interna-
tional Classification of Diseases code 162 (i.e. trachea,
bronchus and lung). The study protocol was approved by
the Independent Scientific Advisory Committee of the GPRD
and the codes used to define lung cancer were reviewed by
an experienced clinician.
Statistical methods
All statistical analyses were performed using SAS version
8.2 (SAS Institute; Cary, NC). We estimated that to match
150 cases each to 5 controls, we could have 80% power to
detect a relative risk of 0.6 assuming 50% of the controls
were users of ICS or ICS/LABA. The use of ICS in controls
was actually higher than this.
We conducted basic descriptive analysis to compare the
cases and controls on demographic and clinical character-
istics at baseline, including: use of other respiratory
medications, comorbidities (including asthma), duration of
both smoking cessation and COPD (Table 2). These were
used as covariates in a multivariate conditional logistic
regression. We also assessed ‘doseeresponse’ relationships
by comparing SABD regular users with those who used 1e2
and 3þ prescriptions per year of either ICS/LABA concom-
itantly or ICS without LABA, over the period of observation.
Results
We identified 7079 patients who met study entry criteria, of
whom 127 had developed lung cancer by 2005 with mean,
25th, median and 75th percentiles duration from index date
to diagnosis as 1062.57, 469, 810 and 1467 days, respec-
tively. The cases were individually matched to 1470
controls (Table 2). On average, patients were 71 years of
age, approximately one-third were female, the mean
duration of COPD was 1.5 years and the mean duration of
smoking cessation was greater than 2 years. Overall, 335
patients were regular users of ICS/LABA concomitantly, 841
were regular users of ICS without LABA, and 421 wereregular users SABD only. Regular users of ICS/LABA and ICS
alone in the first 6 months of cohort entry remained users of
the corresponding therapies during their observation
periods (data not shown). Indeed, the matched patients
were found to be continuously exposed to their respective
therapies during each subsequent year of observation, with
over 90% having two or more prescriptions per year.
Among regular ICS/LABA users, 20 (6.0%) were diagnosed
with lung cancer, compared with 61 (7.3%) of regular ICS
88 V.A. Kiri et al.users and 46 (10.9%) of regular SABD users. Using multi-
variate conditional regression analysis, the adjusted hazard
ratio estimates for lung cancer risk were 0.50 (95% CI,
0.27e0.90) for ICS/LABA users and 0.64 (95% CI, 0.42e0.98)
for ICS users, compared with SABD users.
‘Doseeresponse’ relationships were observed in both
ICS/LABA and ICS users when compared with non-users.
Hazard ratios were 0.75 (95% CI, 0.33e1.75) and 0.88
(95% CI, 0.51e1.52) in those who used one or two
prescriptions per year of ICS/LABA and ICS, respectively,
and 0.39 (95% CI, 0.19e0.79) and 0.51 (95% CI, 0.30e0.84)
in those who used three or more prescriptions per year of
the corresponding therapies (Fig. 1).
Discussion
In this observational study involving ex-smokers with COPD,
concomitant regular use of ICS/LABA was associated with
a reduced risk of lung cancer. Lung cancer risk was reduced
by 50% in ICS/LABA users and by 36% in ICS users, compared
with SABD users. Additionally, when considering the
number of prescriptions, lung cancer risk decreased with
increasing number of prescriptions in both ICS/LABA and ICS
users compared with non-users, from a non-significant
reduction of 25% in those with one or two prescriptions to
a 61% risk reduction in patients with three or more
prescriptions per year among ICS/LABA users; and from
a non-significant reduction of 12% in those with one or two
prescriptions to a 49% risk reduction in patients with three
or more prescriptions per year among ICS users.
There are strengths and limitations of our study worth
considering. Lung cancer cases were diagnosed by specialist
hospital doctors and recorded in GPRD by the GP, therefore
the risk of false-positive misclassification bias is likely to be
very low. However, it is unknown what proportion, if any, of
diagnosed cases were not recorded by the GP leading to
false-negative misclassification (and bias towards a null
association if nondifferential). In addition, smoking can
obscure or counter potential benefits of inhaled therapy,0
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Figure 1 Hazard ratios with 95% confidence intervals from a multi
illustrating dose response relationship for ICS/LABA and ICS use, atherefore the focus of the study on patientswhowere former
smokers is unique.33 This study involved a population-based
sample and the use of clinically reviewedmedical codes, and
analysis of retrospective electronic medical record data
collected independently of this research question.
An important limitation of the study is the lack of
adjustment in statistical models for important risk factors
not fully recorded in the GPRD, e.g. detailed patient history
of tobacco use, symptoms, occupational exposures, socio-
economic status and pulmonary function. This gap in
information could potentially result in biased effect esti-
mates due to residual confounding, if these factors are
associated with both the prescribing of ICS with or without
LABA and the risk of lung cancer.34 Additional limitations
are the lack of valid information on lung cancer type, and
relatively short length of follow-up.
Some of the results of the current study have been
previously reported as an abstract35 and so also were those
from an alternative study design.36 These results support
previous clinical trial findings. A meta-analysis pooling
individual data from seven randomised ICS placebo-
controlled trials focused on all-cause mortality found
a trend towards a lower risk of cancer-related mortality.37
Of 42 deaths from cancers (21% of all causes), 33 (79%) were
due to lung cancer, and the adjusted hazard ratio (95% CI)
for cancer mortality between ICS versus placebo was 0.55
(0.29e1.03). This meta-analysis also suggested that ICS
might be more effective in former than in current smokers,
concluding that for patients with COPD to experience
maximal benefit from ICS, cessation of smoking is of prime
importance. In murine models, corticosteroids have also
been shown to modulate proto-oncogene expression and to
inhibit tumour growth by as much as 70%.38 Furthermore,
usage of ICS over 6 months has been shown to reduce
prostaglandin E2 levels, a product of COX-2 pathways, and
to down-regulate proto-oncogene (for example, BCL2)
expression in the airways of smokers.39
A recent study by Parimon et al. investigated the effects
of ICS alone on the reduction in risk of lung cancer.40 Theero
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variate conditional logistic regression model on lung cancer risk
nd influence of covariates.
ICS and lung cancer risk in COPD 89hazard ratio was 0.81 (95% CI, 0.51e1.26) for ICS versus
non-ICS users, suggesting a non-statistically significant
reduction in risk of lung cancer. Of note, a doseeresponse
relationship between ICS exposure and lung cancer risk was
observed, and higher doses of ICS were associated with
a decreased risk of lung cancer (adjusted hazard ratio for
<1200 mg/day: 1.13 [95% CI, 0.67e1.90]; 1200 mg/day
0.39 [95% CI, 0.16e0.96]). The level of risk reduction in the
higher dose category is of the same magnitude as the
estimates reported in our study for those with three or
more prescriptions per year.
If confirmed with a higher level of evidence, the findings
from this pharmacoepidemiology study might have clear
implications for the management of COPD patients and
current promotional efforts on smoking cessation. The
potential for a combination of smoking cessation and
pharmacologic treatment to reduce incidence of lung
cancer provides an additional incentive to manage COPD
effectively to reduce the overall burden of the disease for
patients and healthcare systems.
The mechanisms by which ICS/LABA may reduce the
incidence of lung cancer remain theoretical and further
research is warranted. Additionally, this study focussed on
patients who GP’s had classified as former smokers, and
a similar study to investigate the magnitude of effect on
reduction in lung cancer risk associated with ICS/LABA in
COPD patients who have continued smoking would also be
of interest. Ultimately, to overcome the limitations of
observational study designs, these results need to be
confirmed in prospective, adequately powered and long-
term randomised clinical trials.
COPD is now thought of as an inflammatory disease.
Anti-inflammatory therapy is used to treat respiratory
disorders, and some studies suggest that it may also
improve survival in patients with COPD.37,24 Additionally, an
association between inflammation and lung cancer has
been proposed, leading to the hypothesis that inhaled anti-
inflammatory therapy may reduce the risk of developing
lung cancer in patients with COPD. Our results suggest that
the use of ICS, particularly concomitant use with an LABA,
may be associated with reduced incidence of lung cancer.
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